Learn more about the small molecule capabilities at our Nansha, China site. Its core capabilities are in clinical and commercial manufacture, with about 90% of its customer base is in Europe and North America. In response to the growing demand for HPAPIs, in the past couple of years, significant investments have been made in development and GMP labs there to manufacture small-scale batches of HPAPIs. A wider mid-scale capacity expansion there, too, is designed to ensure a smooth transition between early-stage manufacturing and the large-scale requirements for commercial supply.

You may also be interested in:
Watch our presentation

Watch on-demand
Latest content
Latest briefing from the Knowledge Center